Role of circulating tumor cell clusters in patients with metastatic hormone-sensitive prostate cancer receiving a gonadotropin-releasing hormone antagonist: A pilot study

作     者：Yuki Kohada Hiroki Kusumoto Takashi Kukimoto Jotaro Mikami Jun Ito Katsutoshi Asano Toru Yaegashi Kanichi Nakagawara Jun Teishima Yasuhiro Kaiho Nobuyuki Hinata Yasuhiro Nakamura Makoto Sato Yuki Kohada;Hiroki Kusumoto;Takashi Kukimoto;Jotaro Mikami;Jun Ito;Katsutoshi Asano;Toru Yaegashi;Kanichi Nakagawara;Jun Teishima;Yasuhiro Kaiho;Nobuyuki Hinata;Yasuhiro Nakamura;Makoto Sato

作者机构：Division of UrologyFaculty of MedicineTohoku Medical and Pharmaceutical UniversitySendaiJapan Department of UrologyHiroshima University Graduate School of Biomedical SciencesHiroshimaJapan Nihon Gene Research Laboratories IncSendaiJapan Division of PathologyFaculty of MedicineTohoku Medical and Pharmaceutical UniversitySendaiJapan 

出 版 物：《Asian Journal of Urology》 (亚洲泌尿外科杂志（英文）)

年 卷 期：2023年第10卷第2期

页      面：210-212页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：patients metastatic cancer 

摘      要：Dear Editor,Prostate cancer is the most common cancer among men[1].Androgen deprivation therapy(ADT)has remained the primary treatment of metastatic-hormone-sensitive prostate cancer(mHSPC),providing a temporary disease control in the majority of *** initial ADT response,castration-resistance prostate cancer(CRPC)still *** study have attempted to determine possible biomarkers for poor prognosis in patients with CRPC[2].